In our study, HER2/neu gene expression is more commonly seen in stage III disease (42% in stage III versus 26% in stage IV), unlike other studies where HER2/neu gene expression is significantly more seen in stage IV of gastric cancer with a larger tumour mass, that can be partly explained by slightly higher numbers of patients with stage III disease (Azarhoosh et al., 2017). The gene discussed is ERBB2; the disease is neoplasm.